Search results
Breaking News, Business, Financial and Economic News, World News from EconoTimes
EconoTimes· 9 hours agoEconoTimes is a fast growing non-partisan source of news and intelligence on global economy and...
Azenta Announces Collaboration with the Crohn's & Colitis Foundation to Support its Crohn's Disease...
The Woonsocket Call· 18 hours agoAzenta, Inc. (Nasdaq: AZTA) today announced it has been selected by the Crohn's & Colitis Foundation (the "Foundation") as its sample management services provider for two of its large-scale ...
... with an Antibody-Drug Conjugate from Phase 1 ASPEN-07 Clinical Trial in Patients with Advanced...
Benzinga· 3 days agoEvorpacept in combination with PADCEV®, an approved antibody-drug conjugate ("ADC"), demonstrated promising activity and was generally well toleratedCompany to host conference call and webcast with Samuel A. Funt,
Is Taysha Gene Therapies, Inc. (NASDAQ:TSHA) the Best Gene Therapy Company?
Insider Monkey via Yahoo Finance· 2 days agoWe recently compiled a list of the 9 Best Gene Therapy Stocks to Buy Now and in this article, we...
Neoadjuvant immunotherapy for early stage melanoma shows positive results
Medical Xpress· 2 days agoThe NADINA study, led by researchers from the Netherlands Cancer Institute, was named one of the...
Immunofoco Biotech to Unveil Solid Tumor CAR-T Programs Clinical Trial Data at 2024 ASCO Meeting
The Parsons Sun· 4 days agoThe company will showcase the latest clinical trial findings for IMC001 in a poster presentation and for IMC002 in an online presentation during the ASCO ...
New Lung Cancer Drug Trial Hailed As Best Result Ever, Setting A “New Benchmark”
IFLScience· 2 days agoThe drug is called lorlatinib, and the trial team says it’s setting a “new benchmark for targeted...
J&J’s seltorexant meets all endpoints in Phase III MDD trial
Clinical Trials Arena via Yahoo Finance· 6 days agoThe MDD market is a...anticipated introduction of late-stage pipeline products. GlobalData is the...
Penny Stocks That Insiders Are Loading Up On: 3 Names to Watch Closely
InvestorPlace· 3 hours agoPenny stocks are risky. It’s why we attach a warning to the tail-end of penny stock articles and why...
Arbutus' Imdusiran with Short Course Interferon Achieves Sustained Undetectable HBsAg, a Necessity...
Benzinga· 7 hours agoAt the end of treatment, 33.3% of patients receiving imdusiran for 48 weeks, interferon (IFN) for 24 weeks and ongoing nucleoside analogue (NA) therapy achieved undetectable levels of HBsAg that were maintained in 100%